Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of many tumor types, and durable responses can be observed in select populations.However, patients may exhibit significant immune-related adverse events (irAEs) that may lead to morbidity.There is limited information on whether the presence of specific germline mutations may